The Role of Chemokines in Hodgkin's Disease

References

• Teruya-Feldstein J., Jaffe E. S., Burd P. R., Kingraa D. W., Setsuda J. E., Tosato G. Differentia] chemokine expression in tissues involved by Hodgkin's disease: direct correlation of eotaxin expression and tissue eosinophilia. Blood 1999; 93: 2463–2470
   PubMed Web of Science ®Google Scholar
• Rollins B. J. Chemokines. Blood 1997; 90: 909–928
   PubMed Web of Science ®Google Scholar
• Baggiolini M. Chemokines and leukocyte traffic. Nature 1998; 392: 565–568
   PubMed Web of Science ®Google Scholar
• Luster A. D. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436–445
   PubMed Web of Science ®Google Scholar
• Gruss H. J., Herrmann F., Drexler H. G. Hodgkin's disease: a cytokine-producing tumor-a review. Crit Rev Oncog 1994; 5: 473–538
   PubMed Web of Science ®Google Scholar
• Gorschluter M, Bohlen H., Hasenclever D., Diehl V., Tesch H. Serum cytokine levels correlate with clinical parameters in Hodgkin's disease. Ann Oncol 1995; 6: 477–482
   PubMed Web of Science ®Google Scholar
• Foss H. D., Herbst H., Gottstein S., Demel G., Araujo I., Stein H. Interleukin-8 in Hodgkin's disease. Preferential expression by reactive cells and association with neutrophil density. Am J Pathol 1996; 148: 1229–1236
   PubMed Web of Science ®Google Scholar
• Gruss H. J., Pinto A., Duyster J., Poppema S., Herrmann F. Hodgkin's disease: a tumor with disturbed immunological pathways. Immunol Today 1997; 18: 156–163
   PubMedGoogle Scholar
• Angiolillo A. L., Sgadari C., Taub D. D., Liao F., Farber J. M., Maheshwari S., Kleinman H. K., Reaman G. H., Tosato G. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995; 182: 155–162
   PubMed Web of Science ®Google Scholar
• Sgadari C, Angiolillo A. L., Cherney B. W., Pike S. E., Farber J. M., Koniaris L. G., Vanguri P., Burd P R., Sheikh N., Gupta G., Teruya-Feldstein J., Tosato G. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci USA 1996; 93: 13791–13796
   PubMed Web of Science ®Google Scholar
• Sgadari C, Farber J. M., Angiolillo A. L., Liao R., Teruya-Feldstein J., Burd P R., Yao L., Gupta G., Kanegane C., Tosato G. Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 1997; 89: 2635–2643
   PubMed Web of Science ®Google Scholar
• Teruya-Feldstein J., Jaffe E. S., Burd P. R., Kanegane H., Kingma D. W., Wilson W. H., Longo D. L., Tosato G. The role of Mig, the monokine induced by interferon-gamma, and IP-10, the interferon-gamma-inducible protein-10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease. Blood 1997; 90: 4099–4105
   PubMed Web of Science ®Google Scholar
• Setsuda J., Teruya-Feldstein J., Harris N. L., Ferry J. A., Sorbara L., Gupta G., Jaffe E. S., Tosato G. Interleukin- 18, interferon-gamma, IP-10, and Mig expression in Epstein- Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease. Am J Pathol 1999; 155: 257–265
   PubMed Web of Science ®Google Scholar
• Luciani M. G., Stoppacciaro A., Peri G., Mantovani A., Ruco L. P. The monocyte chemotactic protein a (MCP-1) and interleukin 8 (IL-8) in Hodgkin's disease and in solid tumours. Mol Pathol 1998; 51: 273–276
   PubMedGoogle Scholar
• Van den Berg A., Visser L., Poppema S. High expression of the CC chemokine TARC in Reed-Steinberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. Am J Pathol 1999; 154: 1685–1691
   PubMed Web of Science ®Google Scholar
• Kapp U., Yeh W. C., Patterson B., Elia A. J., Kagi D., Ho A., Hessel A., Tipsword M., Williams A., Mirtsos C., Itie A., Moyle M., Mak T. W. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 1999; 189: 1939–1946
   PubMed Web of Science ®Google Scholar
• Kingma D. W., Weiss W. B., Jaffe E. S., Kumar S., Frekko K., Raffeld M. Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus—associated lymphoproliferative disorders and malignant lymphomas. Blood 1996; 88: 242–251
   PubMed Web of Science ®Google Scholar
• Harris N. L., Jaffe E. S., Stein H., Banks P. M., Chan J. K., Cleary M. L., Delsol G., De Wolf-Peeters C., Falini B., Gatter K. C. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• Harris N. L. Hodgkin's lymphomas: classification, diagnosis, and grading [In Process Citation]. Semin Hematol 1999; 36: 220–232
   PubMed Web of Science ®Google Scholar
• Jaffe E. S., Harris N. L., Diebold J., Muller-Hermelink H. K. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Pathol 1999; 111: S8–12
   PubMed Web of Science ®Google Scholar
• Jaffe E. S. Hematopathology: integration of morphologic features and biologic markers for diagnosis. Mod Pathol 1999; 12: 109–115
   PubMed Web of Science ®Google Scholar
• Rudiger T., Jaffe E. S., Delsol G., DeWolf-Peeters C., Gascoyne R. D., Georgii A., Harris N. L., Kadin M. E., MacLennan K. A., Poppema S., Stein H., Weiss L. E., Muller-Hermelink H. K. Workshop report on Hodgkin's disease and related diseases (“grey zone” lymphoma). Ann Oncol 1998; 9: S31–38
   Google Scholar
• Hsu S. M., Hsu P. L. Lack of effect of colony-stimulating factors, interleukins, interferons, and tumor necrosis factor on the growth and differentiation of cultured Reed-Stemberg cells. Comparison with effects of phorbol ester and retinoic acid. Am J Pathol 1990; 136: 181–189
   PubMed Web of Science ®Google Scholar
• Merz H., Fliedner A., Orscheschek K., Binder T., Sebald W., Muller-Hermelink H. K., Feller A. C. Cytokine expression in T-cell lymphomas and Hodgkin's disease. Its possible implication in autocrine or paracrine production as a potential basis for neoplastic growth. Am J Pathol 1991; 139: 1173–1180
   PubMed Web of Science ®Google Scholar
• Loetscher M., Gerber B., Loetscher P., Jones S. A., Piali L., Clark-Lewis I., Baggiolini M., Moser B. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes [see comments]. J Exp Med 1996; 184: 963–969
   PubMed Web of Science ®Google Scholar
• Liao F., Rabin R. L., Yannelli J. R., Koniaris L. G., Vanguri P., Farber J. M. Human Mig chemokine: biochemical and functional characterization. J Exp Med 1995; 182: 1301–1314
   PubMed Web of Science ®Google Scholar
• Morente M. M., Piris M. A., Abraira V., Acevedo A., Aguilera B., Bellas C., Fraga M., Garcia-Del-Moral R., Gomez-Marcos F., Menarguez J., Oliva H., Sanchez-Beato M., Montalban C. Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high K167 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression. Blood 1997; 90: 2429–2436
   PubMed Web of Science ®Google Scholar
• Kaplan G., Luster A. D., Hancock G., Cohn Z. A. The expression of a gamma interferon-induced protein (IP-10) in delayed immune responses in human skin. J Exp Med 1987; 166: 1098–1108
   PubMed Web of Science ®Google Scholar
• Vanguri P., Farber J. M. IFN and virus-inducible expression of an immediate early gene, crg-2/IP-10, and a delayed gene, I-A alpha in astrocytes and microglia. J Immunol 1994; 152: 1411–1418
   PubMed Web of Science ®Google Scholar
• Haluska F. G., Brufsky A. M., Canellos G. P. The cellular biology of the Reed-Stemberg cell [see comments]. Blood 1994; 84: 1005–1019
   PubMed Web of Science ®Google Scholar
• Klein S., Jones D. B., Tesch H. In vitro differentiation of a Hodgkin's disease derived cell line. Hematol Oncol 1992; 10: 195–205
   PubMed Web of Science ®Google Scholar
• Rothenberger S., Bachmann E., Berger C., McQuain C., Odermatt B. F., Knecht H. Natural 30 base pair and 69 base pair deletion variants of the LMP1 oncogene do stimulate NF-kappaB-mediated transcription. Oncogene 1997; 14: 2123–2126
   PubMed Web of Science ®Google Scholar
• Devergne O., Hatzivassiliou E., Izumi K. M., Kaye K. M., Kleijnen M. F., Kieff E., Mosialos G. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol Cell Biol 1996; 16: 7098–7108
   PubMed Web of Science ®Google Scholar
• Huen D. S., Henderson S. A., Croom-Carter D., Rowe M. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 1995; 10: 549–560
   PubMed Web of Science ®Google Scholar
• Chemey B. W., Sgadari C., Kanegane C., Wang F., Tosato G. Expression of the Epstein-Barr virus protein LMP1 mediates tumor regression in vivo. Blood 1998; 91: 2491–2500
   PubMed Web of Science ®Google Scholar
• Dreschfeld J. Clinical lecture on acute Hodgkin's disease. British Medical Journal 1892; 1: 893
   PubMedGoogle Scholar
• Samoszuk M., Nansen L. Detection of inter-leukin-5 messenger RNA in Reed-Stemberg cells of Hodgkin's disease with eosinophilia. Blood 1990; 75: 13–16
   PubMed Web of Science ®Google Scholar
• Rot A., Krieger M., Brunner T., Bischoff S. C., Schall T. J., Dahinden C. A. RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes. J Exp Med 1992; 176: 1489–1495
   PubMed Web of Science ®Google Scholar
• Pinto A., Aldinucci D., Gloghini A., Zagonel V, Degan M., Improta S., Juzbasic S., Todesco M., Perm V., Gattei V., Herrmann E., Gruss H. J., Carbone A. Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood 1996; 88: 3299–3305
   PubMed Web of Science ®Google Scholar
• Wardlaw A. J., Moqbel R., Cromwell O., Kay A. B. Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. J. Clin Invest 1986; 78: 1701–1706
   PubMed Web of Science ®Google Scholar
• Rothenberg M. E., Luster A. D., Leder P. Murine eotaxin: an eosinophil chemoattractant inducible in endothelial cells and in interleukin 4-induced tumor suppression. Proc Natl Acad Sci US A 1995; 92: 8960–8964
   PubMed Web of Science ®Google Scholar
• Rothenberg M. E., Ownbey R., Mehlhop P. D., Loiselle P. M., Van de Rijn M., Bonventre J. V., Oettgen H. C., Leder P., Luster A. D. Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice. Mol Med 1996; 2: 334–348
   PubMed Web of Science ®Google Scholar
• Garcia-Zepeda E. A., Rothenberg M. E., Ownbey R. T., Celestin J., Leder P., Luster A. D. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 1996; 2: 449–456
   PubMed Web of Science ®Google Scholar
• Chen J., Akyurek L. M., Fellstrom B., Hayry P., Paul L. C. Eotaxin and capping protein in experimental vasculopathy. Am J Pathol 1998; 153: 81–90
   PubMed Web of Science ®Google Scholar
• Uguccioni M., Loetscher P., Forssmann U., Dewald B., Li H., Lima S. H., Li Y., Kreider B., Garotta G., Thelen M., Baggiolini M. Monocyte chemotactic protein 4 (MCP-4), a novel structural and functional analogue of MCP-3 and eotaxin. J Exp Med 1996; 183: 2379–2384
   PubMed Web of Science ®Google Scholar
• Patel V. P., Kreider B. L., Li Y., Li H., Leung K., Salcedo T., Nardelli B., Pippalla V., Gentz S., Thotakura R., Parmelee D., Gentz R., Garotta G. Molecular and functional characterization of two novel human C-C chemokines as inhibitors of two distinct classes of myeloid progenitors. J Exp Med 1997; 185: 1163–1172
   PubMed Web of Science ®Google Scholar
• Pardigol A., Forssmann U., Zucht H. D., Loetscher P., Schulz-Knappe P., Baggiolini M., Forssmann W. G., Magert H. J. HCC-2, a human chemokine: gene structure, expression pattern, and biological activity. Proc Natl Acad Sci USA 1998; 95: 6308–6313
   PubMed Web of Science ®Google Scholar
• Dunzendorfer S., Schratzberger P., Reinisch N., Kahler C. M., Wiedermann C. J. Secretoneurin, a novel neuropeptide, is a potent chemoattractant for human eosinophils. Blood 1998; 91: 1527–1532
   PubMed Web of Science ®Google Scholar
• Forssmann U., Uguccioni M., Loetscher P., Dahinden C. A., Langen H., Thelen M., Baggiolini M. Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes. J Exp Med 1997; 185: 2171–2176
   PubMed Web of Science ®Google Scholar
• Daugherty B. L., Siciliano S. J., DeMartino J. A., Malkowitz L., Sirotina A., Springer M. S. Cloning, expression, and characterization of the human eosinophil eotaxin receptor. J Exp Med 1996; 183: 2349–2354
   PubMed Web of Science ®Google Scholar
• Ponath P. D., Qin S., Post T. W., Wang J., Wu L., Gerard N. P., Newman W., Gerard C., Mackay C. R. Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils [see comments]. J Exp Med 1996; 183: 2437–2448
   PubMed Web of Science ®Google Scholar
• Teixeira M. M., Wells T. N., Lukacs N. W., Proudfoot A. E., Kunkel S. L., Williams T. J., Hellewell P. G. Chemokine-induced eosinophil recruitment. Evidence of a role for endogenous eotaxin in an in vivo allergy model in mouse skin. J Clin Invest 1997; 100: 1657–1666
   PubMed Web of Science ®Google Scholar
• White J. R., Imburgia C., Dul E., Appelbaum E., O'Donnell K., O'Shannessy D. J., Brawner M., Fomwald J., Adamou J., Elshourbagy N. A., Kaiser K., Foley J. J., Schmidt D. B., Johanson K., Macphee C., Moores K., McNulty D., Scott G. F., Schleimer R. P., Sarau H. M. Cloning and functional characterization of a novel human CC chemokine that binds to the CCR3 receptor and activates human eosinophils. J Leukoc Biol 1997; 62: 667–675
   PubMed Web of Science ®Google Scholar
• Sallusto F., Mackay C. R., Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 1997; 277: 2005–2007
   PubMed Web of Science ®Google Scholar
• Gerber B. O., Zanni M. P., Uguccioni M., Loetscher M., Mackay C. R., Pichler W. J., Yawalkar N., Baggiolini M., Moser B. Functional expression of the eotaxin receptor CCR3 in T lymphocytes co- localizing with eosinophils. Curr Biol 1997; 7: 836–843
   PubMed Web of Science ®Google Scholar
• Teruya-Feldstein J., Jaffe E. S., Berkowitz J. R., Burd P. R., Tosato G. Eotaxin-1, a Specific Chemoattractant for Eosinophils in Hodgkin's Disease. BLOOD 1997; 90: 388a
   Google Scholar
• Jundt E, Anagnostopoulos I., Bommert K., Emmerich F, Muller G., Foss H.-D., Royer H.-D., Stein H., Dorken B. Hodgkin/Reed-Sternberg Cells Induce Fibroblasts to Secrete Eotaxin, a Potent Chemoattractant for T Cells and Eosinophils. BLOOD 1999; 94: 2065–2071
   PubMed Web of Science ®Google Scholar
• Enblad G., Sundstrom C., Glimelius B. Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis. Hematol Oncol 1993; 11: 187–193
   PubMed Web of Science ®Google Scholar
• Toth J., Dworak O., Sugar J. Eosinophil predominance in Hodgkin's disease. Z. Krebsforsch Klin Onkol Cancer Res Clin Oncol 1977; 89: 107–111
   PubMed Web of Science ®Google Scholar
• Von Wasielewski R., Seth S., Franklin J., Fischer R., Hubner K., Hansmann M., Diehl V., Georgii A. Tissue Eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood 1999, In press
   Web of Science ®Google Scholar
• Rodenburg R. J., Brinkhuis R. F., Peek R., Westphal J. R., Van Den Hoogen F. H., Van Venrooij W. J., Van de Putte L. B. Expression of macrophage-derived chemokine (MDC) mRNA in macrophages is enhanced by inter-leukin-lbeta, tumor necrosis factor alpha, and lipopolysac-charide. J Leukoc Biol 1998; 63: 606–611
   PubMed Web of Science ®Google Scholar
• Godiska R., Chantry D., Raport C. J., Sozzani S., Allavena P., Leviten D., Mantovani A., Gray P. W. Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J Exp Med 1997; 185: 1595–1604
   PubMed Web of Science ®Google Scholar
• Ghia P., Schaniel C., Rolink A. G., Nadler L. M., Cardoso A. A. Human macrophage-derived chemokine (MDC) is strongly expressed following activation of both normal and malignant precursor and mature B cells. Curr Top Microbiol Immunol 1999; 246: 103–110
   PubMed Web of Science ®Google Scholar
• Andrew D. P., Chang M. S., McNinch J., Wathen S. T., Rihanek M., Tseng J., Spellberg J. P., Elias C. G., 3rd. STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13. J Immunol 1998; 161: 5027–5038
   PubMed Web of Science ®Google Scholar
• Doucet C., Brouty-Boye D., Pottin-Clemenceau C., Canonica G. W., Jasmin C., Azzarone B. Inter-leukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. J Clin Invest 1998; 101: 2129–2139
   PubMed Web of Science ®Google Scholar
• Angiolillo A. L., Sgadari C., Sheikh N., Reaman G. H., Tosato G. Regression of experimental human leuke-mias and solid tumors induced by Epstein-Barr virus-immortalized B cells. Leulc Lymphoma 1995; 19: 267–276
   PubMed Web of Science ®Google Scholar
• Rothenberg M. E., MacLean J. A., Pearlman E., Luster A. D., Leder P. Targeted disruption of the chemokine eotaxin partially reduces antigen- induced tissue eosinophilia. J Exp Med 1997; 185: 785–790
   PubMed Web of Science ®Google Scholar
• Rothenberg M. E. Eosinophilia. N Engl J Med 1998; 338: 1592–1600
   PubMed Web of Science ®Google Scholar